Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development
03 mai 2023 03h00 HE
|
Vaccentis AG
Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
03 mai 2023 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
02 mai 2023 02h00 HE
|
OKYO Pharma LTD
Trial designed with pre-specified primary efficacy endpoints discussed previously with FDAIf successful, this phase 2 trial may serve as one of the two required phase 3 studies necessary to support...
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
25 avr. 2023 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Global Dry Eye Syndrome Treatment Market Report 2023: Growing Investment in the Healthcare Industry Fuel the Sector
17 avr. 2023 11h28 HE
|
Research and Markets
Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Syndrome Treatment - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Indication, By Product Type, By...
Keratoconjunctivitis Sicca (Dry Eye) Clinical Trial Analysis Report 2023: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries
14 avr. 2023 08h53 HE
|
Research and Markets
Dublin, April 14, 2023 (GLOBE NEWSWIRE) -- The "Keratoconjunctivitis Sicca (Dry Eye) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top...
Notice of Intention to Delist From The London Stock Exchange
04 avr. 2023 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Today Announces Director Acquires Shares
29 mars 2023 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Announces PDMR Dealing
24 mars 2023 03h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
16 mars 2023 03h01 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...